* Elicio Therapeutics Inc reported a quarterly adjusted loss of $1.39 per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $-1.27. The mean expectation of three analysts for the quarter was for a loss of 73 cents per share. Wall Street expected results to range from -95 cents to -57 cents per share.
* Reported revenue was zero; analysts expected zero.
* Elicio Therapeutics Inc's reported EPS for the quarter was a loss of $1.39.
* The company reported a quarterly loss of $18.84 million.
* Elicio Therapeutics Inc shares had fallen by 0.4% this quarter and lost 39.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 8.2% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Elicio Therapeutics Inc is $9.50 This summary was machine generated from LSEG data November 14 at 04:12 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.73 -1.39 Missed
Jun. 30 2024 -0.96 -0.64 Beat
Mar. 31 2024 -1.09 -1.15 Missed
Dec. 31 2023 -0.78 -1.75 Missed
Comments